ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer
April 02 2014 - 7:35AM
Business Wire
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the
appointment of Hugh M. Cole to the position of senior vice
president and chief business officer. Mr. Cole will be responsible
for global business and corporate development, licensing and
strategic planning. He will report to ARIAD’s chairman and chief
executive officer, Harvey J. Berger, M.D.
Hugh Cole, senior vice president and
chief business officer at ARIAD Pharmaceuticals (Photo: Business
Wire)
Mr. Cole is a seasoned pharmaceutical executive with more than
25 years of industry experience and a deep background in rare and
orphan pharmaceutical markets. Prior to joining ARIAD, he spent
seven years at Shire Pharmaceuticals, most recently as senior vice
president, strategic planning and program management and as a
global franchise head, and before that, as vice president, business
development. Previously, he held senior positions in business and
corporate development at Oscient Pharmaceuticals (formerly Genome
Therapeutics) and at Millennium Pharmaceuticals and its affiliates.
Mr. Cole led numerous successful acquisitions both at Shire and
Oscient.
“Hugh is a thoughtful and experienced executive who brings great
value to our leadership team,” stated Dr. Berger. “He will be
integral in seeking business and corporate development
opportunities for ARIAD, including a commercial partnership for
Iclusig® in Japan, as well as helping to further maximize our
oncology pipeline.”
Hugh started his career as an investment analyst at Fred Alger
Management and then as a Principal at the Wilkerson Group, a
consulting and advisory firm. He has an AB degree in chemistry from
Harvard and an MBA degree from the Wharton School at the University
of Pennsylvania, focused on healthcare management and finance.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an integrated global
oncology company focused on transforming the lives of cancer
patients with breakthrough medicines. ARIAD is working on new
medicines to advance the treatment of various forms of chronic and
acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer
medicines. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter
(@ARIADPharm).
This press release contains “forward-looking statements”
including, but not limited to, statements about potential new
business and corporate development opportunities and the ongoing
development of our pipeline of cancer medicines. Forward-looking
statements are based on management's expectations and are subject
to certain factors, risks and uncertainties that may cause actual
results, outcome of events, timing and performance to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include, but are not limited to,
risks and uncertainties related to continued growth in market
acceptance of Iclusig, risks and uncertainties associated with
biotechnology drug development, the costs associated with our
research, development, manufacturing and other activities, the
adequacy of our capital resources and the availability of
additional funding, and other factors detailed in the Company's
public filings with the U.S. Securities and Exchange Commission.
The information contained in this press release is believed to be
current as of the date of original issue. The Company does not
intend to update any of the forward-looking statements after the
date of this document to conform these statements to actual results
or to changes in the Company's expectations, except as required by
law.
Iclusig® is registered trademark of ARIAD Pharmaceuticals,
Inc.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20140402005273/en/
ARIAD Pharmaceuticals, Inc.For InvestorsKendra Adams,
617-503-7028Kendra.adams@ariad.comorFor MediaLiza Heapes,
617-621-2315Liza.heapes@ariad.com
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Apr 2023 to Apr 2024